How Gut Bacteria Drive Kidney-Bone Disease and How to Fix It

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a systemic syndrome linking impaired kidney function to disrupted mineral metabolism and deteriorating bone health. This wide-ranging 2026 review published in Frontiers in Endocrinology argues that gut microbiota dysbiosis is not a bystander but a central mechanistic driver of this condition, operating through a newly articulated 'gut-kidney-bone axis.'

The authors conducted a systematic literature search across PubMed, Web of Science, Embase, and Google Scholar, integrating evidence on CKD, gut microbiota, short-chain fatty acids (SCFAs), uremic toxins, and musculoskeletal diseases including osteoporosis (OP), osteoarthritis (OA), and rheumatoid arthritis (RA). The review spans over 264 references and incorporates insights from the 2026 ISAPP consensus on gut health, which redefines dysbiosis as a comprehensive homeostatic disruption at compositional, functional, and host-interaction levels—not merely a shift in bacterial abundance.

A key mechanistic insight is the role of uremic toxins generated by dysbiotic microbiota. Indoxyl sulfate (IS), derived from bacterial metabolism of dietary tryptophan, accumulates massively in CKD due to impaired renal clearance. It activates the aryl hydrocarbon receptor (AhR)–NF-κB and MAPK pathways, inducing oxidative stress, inflammatory cascades, renal fibrosis, endothelial dysfunction, vascular calcification, and impaired bone metabolism. Similarly, TMAO promotes atherosclerosis via macrophage foam cell formation, while p-cresyl sulfate (pCS) disrupts the blood-brain barrier via EGFR/STAT3 signaling. Reduced SCFA production—particularly butyrate, propionate, and acetate from beneficial taxa like Faecalibacterium prausnitzii and Akkermansia muciniphila—further compromises intestinal barrier integrity and systemic immune regulation.

The FGF23-Klotho endocrine axis emerges as a critical link between gut dysbiosis, kidney dysfunction, and bone disorder. PTH dysregulation compounds these effects. The review identifies both 'shared dysbiosis patterns' (e.g., reduced Firmicutes/Bacteroidetes diversity, expansion of Proteobacteria and Enterobacteriaceae) common across CKD, RA, OA, and OP, and disease-specific microbiome signatures that may explain divergent clinical phenotypes. Early-life antibiotic exposure, aging, psychological stress, and physical inactivity are flagged as upstream dysbiosis triggers.

Therapeutically, the review highlights that interventions targeting gut microbiota—probiotics, prebiotics, synbiotics, dietary fiber supplementation, and fecal microbiota transplantation (FMT)—demonstrate meaningful potential to restore gut-kidney-bone axis homeostasis and improve bone outcomes. The authors frame this as the dawn of a 'microbiome medicine era' for managing metabolic bone diseases and CKD comorbidities, while acknowledging that most evidence remains preclinical or from small clinical trials, and that causal directionality in human disease requires further validation.